Do NSAIDs and Other Pain Relief Drugs Can Inhibit the Growth of Lactobacillaceae ?
Hanna Kruszewska
Department of Antibiotics and Microbiology, National Medicines InstituteWarsaw, Poland
Orcid profileSearch for this author on
, Anna Zawistowska-Rojek
Department of Antibiotics and Microbiology, National Medicines InstituteWarsaw, Poland
Orcid profileSearch for this author on
and Stefan Tyski
Department of Antibiotics and Microbiology, National Medicines InstituteWarsaw, Poland
Orcid profileSearch for this author on
Dec 16, 2023
About this article
Article Category: SHORT COMMUNICATION
Published Online: Dec 16, 2023
Page range: 507 - 513
Received: Jul 04, 2023
Accepted: Sep 13, 2023
DOI: https://doi.org/10.33073/pjm-2023-038
Keywords
© 2023 Hanna Kruszewska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The summary of activity in vitro of tested NSAIDs and analgesics against Lactobacillaceae strains_
| Active substance | The lowest inhibitory concentration for a minimum 2 strains |
|---|---|
| Nabumetone | > 3.2 mg/ml |
| Celecoxib | > 3.2 mg/ml |
| Nimesulide | > 3.2 mg/ml |
| Meloxicam | > 3.2 mg/ml |
| Etoricoxib | > 3.2 mg/ml |
| Naproxen | > 3.2 mg/ml |
| Piroxicam | > 3.2 mg/ml |
| Indomethacin | > 3.2 mg/ml |
| Tramadol | > 3.2 mg/ml |
| Paracetamol | > 3.2 mg/ml |
| Acetylsalicylic acid | 3.2 mg/ml |
| Ketoprofen | 0.8 mg/ml |
| Dexketoprofen | 0.8 mg/ml |
| Ibuprofen | 0.4 mg/ml |
| Flurbiprofen | 0.4 mg/ml |
| Diclofenac | 0.05 mg/ml |
Minimal inhibitory concentration (MIC) of selected NSAIDs against 49 Lactobacillaceae strains_
| Species | Source/(number of strains) | MIC (mg/ml) | Acetylsalicylic acid | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Flurbiprofen | Ketoprofen | Dexketoprofen | Ibuprofen | Diclofenac | |||||||||||||||
| 0.4 | 0.8 | 1.6 | 3.2 | 0.8 | 1.6 | 3.2 | 0.8 | 1.6 | 3.2 | 0.4 | 0.8 | 1.6 | 0.05 | 0.1 | 0.2 | 0.8 | 3.2 | ||
| ATCC* 4356™ | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| Probiotic products (n = 10) | 4 | 2 | 4 | 0 | 0 | 9 | 1 | 0 | 9 | 1 | 2 | 5 | 3 | 0 | 5 | 2 | 3 | 10 | |
| Clinical isolates (n = 9) | 0 | 4 | 5 | 0 | 0 | 6 | 3 | 0 | 4 | 5 | 1 | 8 | 0 | 0 | 4 | 5 | 0 | 9 | |
| ATCC* 53103™ | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | |
| Probiotic products (n = 4) | 1 | 3 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 4 | 0 | 4 | 0 | 0 | 1 | 3 | 0 | 4 | |
| Clinical isolates (n = 6) | 0 | 0 | 5 | 1 | 0 | 0 | 6 | 0 | 1 | 5 | 0 | 6 | 0 | 0 | 4 | 2 | 0 | 6 | |
| Probiotic products (n = 4) | 2 | 2 | 0 | 0 | 0 | 3 | 1 | 0 | 4 | 0 | 4 | 0 | 0 | 1 | 3 | 0 | 0 | 4 | |
| Clinical isolates (n = 2) | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | |
| Probiotic products (n = 3) | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | |
| ATCC* 14917™ | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| Probiotic products (n = 3) | 0 | 3 | 1 | 0 | 1 | 2 | 0 | 0 | 3 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | |
| Clinical isolates (n = 4) | 0 | 2 | 1 | 0 | 0 | 4 | 0 | 0 | 4 | 0 | 1 | 3 | 0 | 0 | 3 | 1 | 0 | 4 | |
| Probiotic products (n= 1) | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| TOTAL | 49 | 9 | 22 | 17 | 1 | 4 | 29 | 16 | 4 | 29 | 16 | 19 | 27 | 3 | 2 | 30 | 14 | 3 | 49 |